Health Care

Try Jim Cramer's Action Alerts PLUS
CLICK HERE NOW

PharmaNet Shares Get Hammered

05/01/08 - 12:45 PM EDT

Melissa Davis

OKLAHOMA CITY -- While other healthcare companies posted some weak metrics on Thursday, PharmaNet PDGI may have suffered through the worst quarterly checkup of all.

Once again, PharmaNet has been hit hard by cancelled orders for clinical drug trials. As a result, the Princeton, N.J.-based company swung to a first-quarter loss, badly missing Wall Street estimates. Its stock plunged 30% to a new 52-week low of $16.80 on the news.

Even Smith & Nephew SNN and Cigna CI, plagued by their own quarterly setbacks, escaped that kind of pain.

Indeed, PharmaNet itself hasn't looked this weak for years. In late 2005, the company found itself fighting for survival after Bloomberg raised serious questions about its early-stage drug trials. Since then, the company has reinvented itself -- even adopting a new name -- as it shifted its focus more to late-stage drug trials instead.

Now, however, both of PharmaNet's core businesses appear to be hurting. After reporting heavy cancellations of early-stage trials last quarter, PharmaNet followed up on Thursday with troubling news of cancellations in its late-stage business as well. All told, PharmaNet clients have cancelled almost $60 million worth of late-stage trials during the past two quarters alone.

PharmaNet's first-quarter results took an especially hard hit. Direct revenue, excluding reimbursed out-of-pocket expenses, inched up just 2.4% to $86.8 million in the recent period. On average, analysts were looking for much higher revenue of $94.6 million.

Still, PharmaNet's bottom-line miss proved even worse. The company swung from a profit of $6 million a year ago to a loss of $10.1 million, or 53 cents a share, in the latest period. Thus, the company fell well short of Wall Street's forecast of a solid 30-cent profit for the quarter.

Previous «
1 2 3 4

Headlines & Perspectives

Health Care

Go To Section Home


04/25/08
Tenet Converts a Tough Critic

A longtime analyst bear signals it's time to buy.


04/23/08
HMA Finally Delivers Strong Results

The company's strong quarter comes amid protests that the company has underperformed.


04/23/08
Profit Slumps at WellPoint

The health insurer misses analyst estimates and trims its full-year guidance.


05/19/08
Cramer on Top Searched Stocks: Yahoo!

Yahoo! is among the most searched stocks on TheStreet.com. Here's what Cramer had to say about the stock recently.


05/17/08
Jim Cramer's Best Blogs

Catch up on his thinking on the hottest topics of the past week.


04/26/08
Coming Week: Make or Break

Investors will have to deal with a Fed meeting and another flood of earnings and economic data.


05/19/08
Top Rocket Stocks: Ensco

Ensco International and Echelon have the potential to move higher in coming days.


04/28/08
Monday's Analysts' Upgrades, Downgrades

See who made what calls.


05/19/08
Telecom Giants See a Savior in Video

The addition of video is helping telecom companies compete against cable and satellite companies.


05/19/08
Contract Expiration Tempers Oil's Rise

The June West Texas Intermediate contract reflects selling pressure ahead of Tuesday's expiration. But stocks in the sector are generally trading higher.


05/19/08
Analysts' Upgrades, Downgrades: Amazon

See who made what calls.


Your Recent Quotes: Quote Up0 | Quote Down0
Dow S&P 500 NASDAQ
Oil*
Gold
10 Yr
0.00%
%
%
%
Data delayed 20 min
Sign up for our FREE newsletters now.

Keep on top of the market and the critical information you need to make more profitable investing decisions.

  • Cramer's Daily Booyah!
  • Before the Bell

Privacy Policy

See All Free Newsletters

Premium Stock Ideas
Access Action Alerts Plus to find out Cramer’s latest picks now!